We are live on ! Find out more
SXTC icon

China SXT Pharmaceuticals
SXTC

2 hedge funds and large institutions have $133K invested in China SXT Pharmaceuticals in 2025 Q2 according to their latest regulatory filings, with 2 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

908% more capital invested

Capital invested by funds: $13.1K → $133K (+$119K)

0.07% more ownership

Funds ownership: 0% → 0.07% (+0.07%)

Holders
2
Holders Change
+2
Holders Change %
–
% of All Funds
0.03%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
–
Reduced
–
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
UBS Group
UBS Group
Switzerland
+$114K
2
VF
Virtu Financial
New York
+$22.7K

Top Sellers

No sellers this quarter

SXTC Hedge Fund Activity: Q2 2025 in Review

2 of the 7,616 institutional investors tracked by Wall St. Rank reported a position in China SXT Pharmaceuticals (SXTC) for Q2 2025, worth a combined $133K — up 908% from $13.1K a quarter earlier.

Buyers outnumbered sellers: 2 funds opened new SXTC positions and 0 closed out — a net gain of 2 holders — while 0 added to existing stakes and 0 trimmed.

The largest buyer was UBS Group, opening a new position worth an estimated $114K.

  • 2 institutional investors held China SXT Pharmaceuticals (SXTC) as of Q2 2025, up from 0 in Q1 2025.
  • Funds reported $133K of China SXT Pharmaceuticals stock for Q2 2025, up 908% quarter-over-quarter.
  • 2 funds opened new China SXT Pharmaceuticals positions in Q2 2025 and 0 closed out, a net change of +2 holders.
  • The largest China SXT Pharmaceuticals buyer in Q2 2025 was UBS Group, an estimated $114K added.

Based on aggregated 13F filings for Q2 2025.